I-131 tositumomab

Bibliography

• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717-20
   PubMed Web of Science ®Google Scholar
• Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:161-8
   PubMedGoogle Scholar
• Schouten HC, Qian W, Kvaloy S, High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-27
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-84
   PubMed Web of Science ®Google Scholar
• Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008;45:118-25
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18
   PubMed Web of Science ®Google Scholar
• Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer 1997;80:2311-20
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25(15):1986-92
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-31
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32
   PubMed Web of Science ®Google Scholar
• Ersboll J, Schultz HB, Pedersen-Bjergaard J, Nissen NI. Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression. Eur J Haematol 1989;42:155-63
   PubMed Web of Science ®Google Scholar
• Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 2004;9:160-72
   PubMed Web of Science ®Google Scholar
• Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507-29
   PubMed Web of Science ®Google Scholar
• Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999;11:375-80
   PubMedGoogle Scholar
• Zalutsky MR, Garg PK, Narula AS. Labeling monoclonal antibodies with halogen nuclides. Acta Radiol Suppl 1990;374:141-5
   PubMedGoogle Scholar
• Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. BioDrugs 2003;17:290-5
   PubMed Web of Science ®Google Scholar
• Colcher D. Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med 1998;39(8 Suppl):11S-3S
   PubMed Web of Science ®Google Scholar
• Press OW, Farr AG, Borroz KI, Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12
   PubMed Web of Science ®Google Scholar
• Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390-7
   PubMed Web of Science ®Google Scholar
• Press OW, Shan D, Howell-Clark J, Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123-9
   PubMed Web of Science ®Google Scholar
• Cardarelli PM, Quinn M, Buckman D, Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002;51:15-24
   PubMed Web of Science ®Google Scholar
• Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res 2008;14(15):4925-34
   PubMed Web of Science ®Google Scholar
• Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39(8 Suppl):14S-20S
   PubMed Web of Science ®Google Scholar
• Wahl RL. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications. J Nucl Med 1998;39(8 Suppl):1S
   PubMed Web of Science ®Google Scholar
• Dewaraja YK, Wilderman SJ, Koral KF, Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. Cancer Biother Radiopharm 2009;24:417-26
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zasadny KR, Francis IR, Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-81
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Estes J, Zasadny KR, Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259-66
   PubMed Web of Science ®Google Scholar
• Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003;101:391-8
   PubMed Web of Science ®Google Scholar
• Vose JM, Wahl RL, Saleh M, Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-23
   PubMed Web of Science ®Google Scholar
• Horning SJ, Younes A, Jain V, Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-19
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Kauf TL, Zelenetz AD, Vose JM. Treatment of transformed and refractory low-grade lymphoma with BexxarTM therapy is associated with improvements in quality of life. Blood 2001;98:683a
   Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: Median 10 year follow-up results. ASH Annual Meeting Abstracts 20 November 2009, 2009;114:3759
   Google Scholar
• Kaminski MS, Tuck M, Estes J, 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Leonard J, Bexxar radioimmunotherapy produces a substantial number of durable complete responses in patients with multiply relapsed or refractory low grade or transformed low grade non-Hodgkin's lymphoma. Blood 2002;100:356a
   PubMed Web of Science ®Google Scholar
• Link B, Kaminski MS, Coleman M, Leonard JP. Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 2004;22(14 Suppl):562a
   Web of Science ®Google Scholar
• Leonard JP, Coleman M, Kostakoglu L, Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005;23:5696-704
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Braziel RM, Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-9
   PubMed Web of Science ®Google Scholar
• Press OW, Eary JF, Gooley T, A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934-42
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Enke C, Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005;23:461-7
   PubMed Web of Science ®Google Scholar
• Vose J, Bierman P, Bociek G, Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation. J Clin Oncol (Meeting Abstracts) 2007;25(18 Suppl):8013
   Web of Science ®Google Scholar
• Juweid ME, Stadtmauer E, Hajjar G, Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 111In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999;5(10 Suppl):3292S-303S
   PubMed Web of Science ®Google Scholar
• Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides. J Nucl Med 1993;34:1801-10
   PubMed Web of Science ®Google Scholar
• Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 2003;30(2 Suppl 4):10-21
   PubMed Web of Science ®Google Scholar
• Gregory SA, Hohloch K, Gisselbrecht C, Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. Oncologist 2009;14(Suppl 2):4-16
   PubMed Web of Science ®Google Scholar
• Cheson BD. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 2005;19:309-22
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64
   PubMed Web of Science ®Google Scholar
• Iagaru A, Mittra ES, Ganjoo K, 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol 2010;12:198-203
   PubMed Web of Science ®Google Scholar
• Leonard JP, Frenette G, Dillman RO, Gregory SA. Interim safety and efficacy results of BexxarTM in a large multicenter expanded access study. Blood 2001;98:133a
   Web of Science ®Google Scholar
• Leonard JP, Zelenetz AD, Vose JM, (tositumomab and iodine I 131 tositumomab) results in durable long-term responses in patients with poor prognosis, multiple relapsed (Rel) and refractory (Ref) low-grade or transformed low-grade non-Hodgkins Lymphoma (NHL). Blood 2001;98:683a
   Web of Science ®Google Scholar
• Kaminski MS, Gribbin T, Ross CW, I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions. Proc Am Soc Clin Oncol 1998;17:2a
   Google Scholar
• Kaminski MS. Tolerance of treatment subsequent to frontline BexxarTM (tositumomab and iodine I-131 tositumomab) in patients (pts) with follicular lymphoma. Blood 2001;98:603a
   Web of Science ®Google Scholar
• Schenkein DP, Leonard J, Harwood S. Interim safety results of BexxarTM in a large multicenter expanded access study. Proc Am Soc Clin Oncol 2001;20:285a
   Google Scholar
• Gregory SA, Coleman M, Dillman RO. BexxarTM is a well-tolerated therapy in elderly patients with low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 2001;98:605a
   Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW. Multicenter, Phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 1998;92(Suppl 1):316a
   Google Scholar
• Kaminski MS, Gregory SA, Fehrenbacher L. Acute and delayed hematologic toxicities associated with BexxarTM therapy are modest: overall experience in patients with low-grade and transformed low-grade NHL. Blood 2001;98:339a
   Web of Science ®Google Scholar
• Gregory SA, Leonard J, Coleman M, Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I 131 tositumomab therapy. Proc Am Soc Clin Oncol 2003;22:2314a
   Google Scholar
• Gregory SA, Zelenetz AD, Knox SJ, BexxarTM is an effective and well tolerated therapy in elderly patients with non-Hodgkin lymphoma (NHL). Am Soc Clin Oncol 2001;20:285a
   Google Scholar
• Kaminski MS, Bennett J, Tuck M, Lack of treatment-related MDS/AML in patients with follicular lymphoma after frontline therapy with tositumomab and iodine I 131 tositumomab. Proc Am Soc Clin Oncol 2003;22:a2313
   Google Scholar
• Armitage JO, Carbone PP, Connors JM, Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897-906
   PubMed Web of Science ®Google Scholar
• Rutar FJ, Augustine SC, Kaminski MS, Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin Lymphoma 2001;2:164-72
   PubMedGoogle Scholar
• Morschhauser F, Dreyling M, Rohatiner A, Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009;14(Suppl 2):17-29
   PubMed Web of Science ®Google Scholar